tirzepatide surpass cvot 🫀 EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: ✓ Noninferior for MACE ✓ 16% ↓ all-cause mortality ✓ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with

Durch die Verwendung biokompatibler Lipide schtzen Liposomen das Glutathion und ermglichen dessen Transport durch das Lymphsystem, wodurch auch der First-Pass-Metabolismus des Glutathions in der Leber vermieden wird

Common Side Effects Nausea and vomiting Diarrhea or constipation Abdominal pain or discomfort Mild headache Indigestion or heartburn Less Common Side Effects Fatigue or dizziness Swelling at the injection site Temporary appetite changes Serious Side Effects and Warnings Monitoring Tips While Using Semanat Injection Check blood sugar regularly to prevent hypoglycemia

This functionalization enables cartilage-targeted delivery, allowing for selective enrichment of GLP-1RAs at diseased joint sites and facilitating precise therapeutic intervention

GHK-Cu is the most well-characterized of the three in terms of extracellular matrix effects